Lilly’s Obesity Drug Demand Helps Drive Its Remarkable Valuation Rise

Eli Lilly reached a historic valuation milestone as demand grew for its weight-loss treatment Mounjaro, which contributed significantly to recent revenue increases. Market data showed rising sales tied to diabetes and obesity therapies, supporting investor interest in Lilly’s expanding therapeutic portfolio. The company continued advancing multiple late-stage drug candidates that added momentum to valuation gains.